Evaluation of the effect of botulinum toxin A on the physical and mental health of patients with hemifacial spasm.

Neurologia 2024 Vol.39(7) p. 540-548

Wei JS, Hu X, Xia L, Shang J, Han Q, Zhang DY

관련 도메인

Abstract

[BACKGROUND] Hemifacial spasm (HFS) is a debilitating disease characterized by involuntary tonic and clonic contractions of muscles innervated by the facial nerve. Botulinum toxin A (BTX-A) is the first-line option and the most effective medical treatment for HFS. The objective of this study was to evaluate the effect of BTX-A therapy on the physical and mental health of HFS patients.

[METHODS] Participants included 65 HFS patients and 65 matched healthy controls in the study. Cornell Medical Index (CMI) self-assessment questionnaire was used to detect the psychological health of all participants. Local injection of BTX-A was applied, and the Cohen hierarchical criteria were employed to stratify the degree of spasticity, further evaluating the efficacy of BTX-A before and two months after treatment in HFS patients. The HFS patients at two months post-treatment were re-evaluated by CMI self-assessment questionnaire, and the evaluated factors of these patients were compared with those of patients before treatment.

[RESULTS] The scores of somatization, depression, anxiety, inadaptation, sensitivity, anger, tension, M-R, and total scores in the HFS group were significantly higher than those in the control group (all P<0.05). Two months post-treatment, among 65 HFS patients who received with BTX-A treatment, 42 (64.6%) were completely relieved, 16 (24.6%) were significantly relieved, 7 (10.8%) were partially relieved, and 0 (0%) cases were invalid, and the total effective rate was 89.2%. Two months after BTX-A treatment, the scores of somatization, tension, anxiety, depression, sensitivity, M-R and total scores of patients with HFS were lower than those before treatment (all P<0.05).

[CONCLUSIONS] Patients with HFS are often accompanied by somatization, anger, inadaptation, sensitivity, anxiety, depression, and tension. BTX-A can not only alleviate the symptoms of HFS, but also improve the somatization, tension, anxiety, depression, and sensitivity.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 2
해부 muscles innervated scispacy 1
해부 facial nerve scispacy 1
약물 botulinum toxin A C0006050
botulinum toxin type A
scispacy 1
약물 [BACKGROUND] Hemifacial scispacy 1
약물 BTX-A → Botulinum toxin A scispacy 1
약물 CMI → Cornell Medical Index scispacy 1
약물 [CONCLUSIONS] Patients scispacy 1
질환 hemifacial spasm C0278152
Hemifacial Spasm
scispacy 1
질환 HFS → Hemifacial spasm C0278152
Hemifacial Spasm
scispacy 1
질환 spasticity C0026838
Muscle Spasticity
scispacy 1
질환 depression C0011570
Mental Depression
scispacy 1
질환 anxiety C0003467
Anxiety
scispacy 1
질환 anger C0002957
Anger
scispacy 1
질환 disease scispacy 1
기타 botulinum toxin A scispacy 1
기타 patients scispacy 1
기타 M-R scispacy 1

MeSH Terms

Humans; Hemifacial Spasm; Botulinum Toxins, Type A; Female; Male; Middle Aged; Neuromuscular Agents; Adult; Mental Health; Treatment Outcome; Aged; Surveys and Questionnaires; Anxiety; Depression

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문